Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Progression 19% Improvement Relative Risk Progression, pneumonia 27% Oxygen therapy -14% Improvement -23% Recovery, dyspnea 60% Recovery, headache 20% Recovery, sore throat 0% Recovery, nasal discharge 18% Recovery, cough -4% Recovery, sputum 0% Recovery, diarhhea 20% Recovery, myalgia -67% Recovery, arthralgia -1000% Viral clearance -4% primary Ivermectin  Wada et al.  LATE TREATMENT  DB RCT Is late treatment with ivermectin beneficial for COVID-19? Double-blind RCT 214 patients in Japan (August 2020 - October 2021) Wada et al., Frontiers in Medicine, May 2023 Favors ivermectin Favors control

Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial

Wada et al., Frontiers in Medicine, doi:10.3389/fmed.2023.1139046, NCT04703205
May 2023  
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now known with p < 0.00000000001 from 100 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Late treatment (6.6 days after onset/PCR+) RCT with 221 low risk (no deaths) COVID-19 patients in Japan, showing no significant difference in viral clearance with a single dose of ivermectin under fasting. Authors note that a single 200 μg/kg dose under fasting was used as approved in Japan, and that the low dose, single day dosing, and fasting administration (~2.5 times lower plasma concentration according to Guzzo) limit applicability, and that studies with more favorable outcomes generally used a higher dose or multiday dosing. Details of PCR testing are not provided but the very slow clearance within the low risk population suggests a very high Ct value that may not accurately represent any reduction in replication-competent viral load.
An erratum notes a conflict of interest for a reviewer that was a Merck employee:
Viral load measured by PCR may not accurately reflect infectious virus measured by viral culture. Porter show that viral load early in infection was correlated with infectious virus, but viral load late in infection could be high even with low or undetectable infectious virus. Assessing viral load later in infection may underestimate reductions in infectious virus with treatment.
This is the 47th COVID-19 RCT for ivermectin, which collectively show efficacy with p=0.0000002.
This is the 99th of 100 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
risk of progression, 19.0% lower, RR 0.81, p = 0.46, treatment 19 of 106 (17.9%), control 23 of 106 (21.7%), NNT 26, adjusted per study, odds ratio converted to relative risk.
risk of progression, 27.1% lower, RR 0.73, p = 0.47, treatment 7 of 28 (25.0%), control 9 of 29 (31.0%), NNT 17, adjusted per study, odds ratio converted to relative risk, pneumonia for patients w/o pneumonia at baseline.
risk of oxygen therapy, 14.3% higher, RR 1.14, p = 0.46, treatment 22 of 106 (20.8%), control 19 of 106 (17.9%), adjusted per study, odds ratio converted to relative risk.
improvement, 23.5% worse, OR 1.23, p = 0.61, treatment 106, control 106, adjusted per study, inverted to make OR<1 favor treatment, RR approximated with OR.
risk of no recovery, 60.0% lower, RR 0.40, p = 0.17, treatment 4 of 107 (3.7%), control 10 of 107 (9.3%), NNT 18, day 15, dyspnea.
risk of no recovery, 20.0% lower, RR 0.80, p = 1.00, treatment 4 of 107 (3.7%), control 5 of 107 (4.7%), NNT 107, day 15, headache.
risk of no recovery, no change, RR 1.00, p = 1.00, treatment 7 of 107 (6.5%), control 7 of 107 (6.5%), day 15, sore throat.
risk of no recovery, 18.2% lower, RR 0.82, p = 0.81, treatment 9 of 107 (8.4%), control 11 of 107 (10.3%), NNT 53, day 15, nasal discharge.
risk of no recovery, 3.8% higher, RR 1.04, p = 1.00, treatment 27 of 107 (25.2%), control 26 of 107 (24.3%), day 15, cough.
risk of no recovery, no change, RR 1.00, p = 1.00, treatment 18 of 107 (16.8%), control 18 of 107 (16.8%), day 15, sputum.
risk of no recovery, 20.0% lower, RR 0.80, p = 1.00, treatment 4 of 107 (3.7%), control 5 of 107 (4.7%), NNT 107, day 15, diarhhea.
risk of no recovery, 66.7% higher, RR 1.67, p = 0.72, treatment 5 of 107 (4.7%), control 3 of 107 (2.8%), day 15, myalgia.
risk of no recovery, 1000.0% higher, RR 11.00, p = 0.06, treatment 5 of 107 (4.7%), control 0 of 107 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 15, arthralgia.
risk of no viral clearance, 4.2% higher, HR 1.04, p = 0.79, treatment 106, control 106, inverted to make HR<1 favor treatment, Kaplan–Meier, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wada et al., 22 May 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Japan, peer-reviewed, 26 authors, study period August 2020 - October 2021, average treatment delay 6.6 days, dosage 200μg/kg single dose, trial NCT04703205 (history). Contact:
This PaperIvermectinAll
Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial
Tatsuhiko Wada, Makoto Hibino, Hiromi Aono, Shunsuke Kyoda, Yosuke Iwadate, Eri Shishido, Keisuke Ikeda, Nana Kinoshita, Yasuki Matsuda, Sakiko Otani, Ryo Kameda, Kenta Matoba, Miwa Nonaka, Mika Maeda, Yuji Kumagai, Junya Ako, Masayoshi Shichiri, Katsuhiko Naoki, Masato Katagiri, Masashi Takaso, Masatsugu Iwamura, Kazuhiko Katayama, Takeshi Miyatsuka, Yasushi Orihashi, Kunihiro Yamaoka
Frontiers in Medicine, doi:10.3389/fmed.2023.1139046
Background: To investigate whether ivermectin inhibits SARS-CoV-2 proliferation in patients with mild-to-moderate COVID-19 using time to a negative COVID-19 reverse transcription-polymerase chain reaction (RT-PCR) test. Methods: CORVETTE-01 was a double-blind, randomized, placebo-controlled study (August 2020-October 2021) conducted in Japan. Overall, 248 patients diagnosed with COVID-19 using RT-PCR were assessed for eligibility. A single oral dose of ivermectin (200 μg/kg) or placebo was administered under fasting. The primary outcome was time to a negative COVID-19 RT-PCR test result for SARS-CoV-2 nucleic acid, assessed using stratified log-rank test and Cox regression models. Results: Overall, 112 and 109 patients were randomized to ivermectin and placebo, respectively; 106 patients from each group were included in the full analysis set (male [%], mean age: 68.9%, 47.9 years [ivermectin]; 62.3%, 47.5 years [placebo]). No significant difference was observed in the occurrence of negative RT-PCR tests between the groups (hazard ratio, 0.96; 95% confidence interval [CI] 0.70-1.32; p = 0.785). Median (95% CI) time to a negative RT-PCR test was 14.0
Ethics statement The studies involving human participants were reviewed and approved by the IRB of Kitasato University Shirokane Campus, affiliation: Kitasato University. The patients/participants provided their written informed consent to participate in this study. Author contributions KY contributed towards conceptualization and drafting the work. YK contributed towards conceptualization, drafting the work, and revising it critically for important intellectual content. MS, TM, JA, KN, MI, MT, MM, MK, and KK contributed towards conceptualization, drafting the work, and revising it critically for important intellectual content. MH, HA, MN, KI, ES, YI, NK, SK, SO, RK, KM, and YM contributed towards acquisition, analysis, or interpretation of data for the work, drafting the work, and revising it critically for important intellectual content. TW contributed towards conceptualization, acquisition, analysis, or interpretation of data for the work, and drafting the work. YO contributed towards the data analysis, drafting the work, and revising it critically for important intellectual content. All authors provide approval for publication of the content and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could..
Ahmed, Karim, Ross, Hossain, Clemens et al., Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos, Int J Infect Dis, doi:10.1093/qjmed/hcab035
Batiha, Alqahtani, Ilesanmi, Saati, El-Mleeh et al., Avermectin derivatives, pharmacokinetics, therapeutic and toxic dosages, mechanism of action, and their biological effects, Pharmaceuticals (Basel), doi:10.3390/ph13080196
Behera, Patro, Singh, Chandanshive, Ravikumar et al., Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: a matched case-control study, PLoS One, doi:10.1371/journal.pone.0247163
Brookmeyer, Crowley, A confidence interval for the median survival time, Biometrics, doi:10.2307/2530286
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir Res, doi:10.1016/j.antiviral.2020.104787
Chaccour, Casellas, Blanco-Di Matteo, Pineda, Fernandez-Montero et al., The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial, EClinicalMedcine, doi:10.1016/j.eclinm.2020.100720
Guzzo, Furtek, Porras, Chen, Tipping et al., Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J Clin Pharmacol, doi:10.1177/009127002237994
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot, doi:10.1038/s41429-020-0336-z
Hill, Mirchandani, Pilkington, Ivermectin for COVID-19: addressing potential bias and medical fraud, Open Forum Infect Dis, doi:10.1093/ofid/ofab645
Hu, Guo, Zhou, Shi, Characteristics of SARS-CoV-2 and COVID-19
Jermain, Hanafin, Cao, Lifschitz, Lanusse et al., Development of a minimal physiologically-based pharmacokinetic model to simulate lung exposure in humans following oral administration of ivermectin for COVID-19 drug repurposing, J Pharm Sci, doi:10.1016/j.xphs.2020.08.024
Koyama, Tokumasu, Katayama, Saito, Kudo et al., Cross-border transmissions of the Delta substrain AY.29 during Tokyo Olympic and Paralympic games, Front Microbiol, doi:10.3389/fmicb.2022.883849
Krolewiecki, Lifschitz, Moragas, Travacio, Valentini et al., Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial, EClinicalMedicine, doi:10.1016/j.eclinm.2021.100959
Lifschitz, Virkel, Sallovitz, Sutra, Galtier et al., Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle, Vet Parasitol, doi:10.1016/S0304-4017(99)00175-2
Lim, Hor, Tay, Jelani, Tan et al., Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: the I-TECH randomized clinical trial, JAMA Intern Med, doi:10.1001/jamainternmed.2022.0189
Merck, Over 30 Years: The Mectizan ® Donation Program
Mittal, Mittal, Inhaled route and anti-inflammatory action of ivermectin: do they hold promise in fighting against COVID-19? Med Hypotheses, doi:10.1016/j.mehy.2020.110364
Mohan, Tiwari, Suri, Mittal, Patel et al., Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial, J Infect Chemother, doi:10.1016/j.jiac.2021.08.021
Momekov, Momekova, Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens, Biotechnol Equip, doi:10.1080/13102818.2020.1775118
Morgenstern, Redondo, Olavarria, Rondon, Roca et al., Ivermectin as a SARS-CoV-2 pre-exposure prophylaxis method in healthcare workers: a propensity score-matched retrospective cohort study, Cureus, doi:10.7759/cureus.17455
Navarro, Camprubi, Requena-Méndez, Buonfrate, Giorli et al., Safety of high-dose ivermectin: a systematic review and meta-analysis, J Antimicrob Chemother, doi:10.1093/jac/dkz524
Ozer, Goksu, Ulker, Balderas, Mahdi, Effectiveness and safety of ivermectin in COVID-19 patients: a prospective study at a safety-net hospital, Cochrane Database Syst Rev, doi:10.1002/14651858.CD015017
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study, Chest, doi:10.1016/j.chest.2020.10.009
Ravikirti, Pattadar, Raj, Agarwal, Biswas, Evaluation of ivermectin as a potential treatment for mild to moderate COVID-19: a double-blind randomized placebo controlled trial in eastern India, J Pharm Sci, doi:10.18433/jpps32105
Reis, Silva, Silva, Thabane, Milagres et al., Effect of early treatment with ivermectin among patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2115869
Schmith, Zhou, Lohmer, The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Ther, doi:10.1002/cpt.1889
Schulz, Altman, Moher Dfor the CONSORT Group. Statement: updated guidelines for reporting parallel group randomised trials, Clin Epidemiol, doi:10.1016/j.jclinepi.2010.02.005
Srivastava, Singh, Drug repurposing in COVID-19: a review with past, present and future, Metabol Open, doi:10.1016/j.metop.2021.100121
Wang, Levi, Ellis, Hill, Minimum manufacturing costs, national prices, and estimated global availability of new repurposed therapies for coronavirus disease, Open Forum Infect Dis, doi:10.1093/ofid/ofab581
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop